Intern Emerg Med
. 2021 Nov 29.
doi: 10.1007/s11739-021-02870-1. Online ahead of print.
Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry
Francesc Formiga # 1 , Manuel Rubio-Rivas # 2 , José María Mora-Luján 2 , Samara Campos Escudero 3 , Rosa Fernandez Madera Martinez 4 , Manuel Mendez-Bailón 5 , Pedro Durán-Del Campo 6 , Andrea Riaño Pérez 7 , Francisco-Javier García-Sánchez 8 , José Nicolás Alcalá-Pedrajas 9 , Sergio Arnedo Hernández 10 , Almudena Hernández Milian 11 , Ana Latorre Díez 12 , Ricardo Gil Sánchez 13 , Ramon Boixeda 14 , Julio Vicente 15 , Begoña Cortes 16 , Carmen Mella Pérez 17 , María Esther Guisado Espartero 18 , José López Castro 19 , Santiago Rodríguez Suárez 20 , Jose F Varona 21 , Ricardo Gomez-Huelgas 22 , Jose Manuel Ramos-Rincón 23 , SEMI-COVID-19 SEMI-COVID-19 Network
Collaborators, Affiliations
- PMID: 34843073
- DOI: 10.1007/s11739-021-02870-1
Abstract
Acetylsalicylic acid (ASA) is widely used in the treatment and prevention of cardiovascular disorders. Our objective is to evaluate its possible protective role, not only in mortality but also in other aspects such as inflammation, symptomatic thrombosis, and intensive care unit (ICU) admission in hospitalized COVID-19 patients. We realized an observational retrospective cohort study of 20,641 patients with COVID-19 pneumonia collected and followed-up from Mar 1st, 2020 to May 1st, 2021, from the nationwide Spanish SEMI-COVID-19 Registry. Propensity score matching (PSM) was performed to determine whether treatment with ASA affected outcomes in COVID-19 patients. On hospital admission, 3291 (15.9%) patients were receiving ASA. After PSM, 3291 patients exposed to ASA and 2885 not-exposed patients were analyzed. In-hospital mortality was higher in the ASA group (30.4 vs. 16.9%, p < 0.001) in the global sample. After PSM, no differences were found between groups (30.4 vs. 30.3%, p = 0.938). There were no differences in inflammation, symptomatic thrombosis, or ICU admission. In conclusion, ASA intake is not associated with in-hospital mortality or any other health outcome evaluated after applying PSM analysis in a real-world large sample of hospitalized COVID-19 patients.
Keywords: Acetylsalicylic acid; COVID-19; Coronavirus; Mortality.